Eylea beats Avastin and Lucentis for visual acuity in DME patients

19 October 2014

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) and partner Germany’s Bayer (BAYN: DE) saw their shares leap 8.5% to $369.64 and 3.4% to 104.85 euros, respectively, after reporting new clinical trial results showing a favorable profile for their ophthalmic drug Eylea (aflibercept) on Friday.

Regeneron announced that, in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness study in patients with diabetic macular edema (Protocol T), Eylea Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to both bevacizumab (Avastin, from Roche subsidiary Genentech) and ranibizumab injection (Lucentis, from Genentech and Novartis), the primary endpoint of the study.

Outcome better than expected, says RBC analyst

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK